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ORIGINAL ARTICLEPrevalence and molecular epidemiology of Clostridium difﬁcile infection in
ThailandP. Putsathit1, M. Maneerattanaporn2, P. Piewngam3, P. Kiratisin3 and T. V. Riley1,4
1) Microbiology and Immunology, School of Pathology and Laboratory Medicine, The University of Western Australia, Crawley, Western Australia,
Australia, 2) Department of Medicine, 3) Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok,
Thailand and 4) Department of Microbiology, PathWest Laboratory Medicine, Queen Elizabeth II Medical Centre, Nedlands, Western Australia, AustraliaAbstractLittle is known about Clostridium difﬁcile infection (CDI) in Asia generally, and speciﬁcally in Thailand. Given the high prevalence of
inappropriate antibiotic usage in this region, CDI is likely to be common. This study investigated the prevalence and molecular
epidemiology of CDI in Thailand. Stool specimens collected from inpatients with diarrhoea at Siriraj hospital in Bangkok (n = 422) were
cultured on ChromID Cdiff agar and any presumptive C. difﬁcile colonies were identiﬁed, PCR ribotyped and toxin proﬁled. As part of
the routine C. difﬁcile testing at Siriraj Hospital, 370 specimens also underwent testing with the BD MAX Cdiff assay to detect the
presence of tcdB. With direct culture, 105 different isolates of C. difﬁcile were recovered from 23.7% (100/422) of the stool specimens.
The prevalence of toxigenic and nontoxigenic isolates was 9.2% (39/422) and 15.6% (66/422), respectively. Of the toxigenic isolates,
69.2% (27/39) and 30.8% (12/39) were tcdA and tcdB positive (A+B+), and A−B+, respectively; none contained binary toxin genes. The ﬁve
most prevalent ribotypes (RTs) were 014/020 group (17/105), 010 (12/105), 017 (12/105), 039 (9/105) and 009 (6/105). Using toxigenic
culture as the reference standard, the sensitivity, speciﬁcity, positive predictive value and negative predictive value of the BD MAX Cdiff
assay were 68.6, 95.1, 63.2 and 96.1%, respectively. The high proportion of A−B+, RT 017 strains emphasises the need for diagnostic
tests that detect either both toxins or just tcdB. Continued surveillance that involves stool culturing will allow molecular tracking and
assist in elucidating the epidemiology of CDI in Thailand.
© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
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E-mail: thomas.riley@uwa.edu.auIntroductionClostridium difﬁcile is an important aetiologic agent of antibiotic-
associated infectious diarrhoea in the developed world [1]. The
major virulence factor of C. difﬁcile is the production of toxins A
and B [1]. Individuals infected with a toxigenic strain may
remain asymptomatic, or they may develop mild to severe
diarrhoea, colitis and, in rare cases, pseudomembranous colitis© 2016 The Authors. Published by El
This is an open access arti[1]. The traditional risk factors associated with C. difﬁcile
infection (CDI) include advanced age, recent hospitalization and
previous disruptions to the gut microbiome by agents such as
antibiotics [1].
Interest in CDI increased exponentially after highly publi-
cized outbreaks of infection in North America with C. difﬁcile
PCR ribotype (RT) 027 in the early 2000s [2] and the emer-
gence of RT 078 in 2007 [3]. The increased morbidity and
mortality observed sparked major public health concerns,
which continue today [2]. In addition to toxins A and B, RTs
027 and 078 produce a third toxin, binary toxin, the role of
which in disease pathogenesis remains controversial [4]. One
important difference between infection with RTs 027 and 078 is
that the latter often affects individuals who lack traditional risk
factors [3]. RT 078 is associated with community-associatedNew Microbe and New Infect 2017; 15: 27–32
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source of infection outside healthcare facilities [3]. A recent
study reported RT 078 strains isolated from humans and pigs to
be indistinguishable via whole genome sequencing, suggesting
that a zoonosis or anthroponosis may be occurring [5]. Addi-
tionally, food and environmental contamination have also been
suggested as possible sources of infection [6].
In order to monitor the prevalence and molecular charac-
teristics of C. difﬁcile and to elucidate the epidemiology of CDI,
continued surveillance is essential. Currently, most C. difﬁcile
research has been done in North America, Europe and
Australia, and limited data are available for Asian countries,
such as Thailand [7]. Several early prevalence studies conducted
in Thailand used toxin A enzyme immunoassay (EIA) as the sole
method of detection [7]. Given the recently reported high
prevalence of a tcdA-negative, tcdB-positive (A−B+) RT 017
(41.5%) in Thailand and the low sensitivity of EIA [8,9], the
widespread use of toxin A EIA alone is likely to have led to an
underestimation of the true prevalence. Toxigenic culture,
which is a current reference standard for C. difﬁcile detection, is
rarely performed these days because of time and cost con-
straints, while the use of PCR-based techniques has increased
over the years [7]. In addition to a lack of an optimal detection
method, the most recent prevalence study was conducted be-
tween 2010 and 2011 [10] and the most recent molecular
epidemiologic study between 2006 and 2008 [9].
To better understand the current epidemiology of CDI in
Thailand, we investigated the prevalence and molecular char-
acteristics of circulating Thai C. difﬁcile strains and assessed the
performance of the routine diagnostic procedure used at Siriraj
Hospital to detect C. difﬁcile in stool specimens.Materials and MethodsSample collection and transport
Between April and June 2015, as part of the routine pathology
testing at the microbiology department at Siriraj Hospital,
Bangkok, Thailand, a total of 422 nonrepeat diarrhoeal samples
were collected. Of these, 370 and 52 specimens were sub-
mitted for C. difﬁcile testing and non–C. difﬁcile–related tests,
respectively. All samples were obtained from patients aged 18
years who experienced clinically signiﬁcant diarrhoea as deﬁned
by at least 3 diarrhoeal bowel movements in the prior 24 hours
corresponding to Bristol stool chart grade 6–7, or a single
diarrhoeal bowel movement corresponding to Bristol stool
chart grade 6–7 and associated with abdominal pain and/or
cramping. After routine C. difﬁcile testing at Siriraj Hospital
(described below), all diarrhoeal samples were sent to a
C. difﬁcile reference laboratory in Perth, Western Australia.© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
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transportation.
Detection of C. difﬁcile toxin B gene in stool specimens
All specimens submitted for C. difﬁcile testing (n = 370) were
subjected to tcdB detection using the BD MAX Cdiff assay (BD
Diagnostic, Franklin Lakes, NJ, USA). This was done as per the
manufacturer’s instruction and as part of routine pathology
testing at Siriraj Hospital.
Isolation and identiﬁcation of C. difﬁcile
At the C. difﬁcile reference laboratory, stool specimens were
cultured both directly on C. difﬁcile ChromID agar (bioMérieux,
Marcy l’Etoile, France) and in a cooked meat enrichment broth
containing gentamicin (5 mg/L), cefoxitin (10 mg/L), cycloserine
(200 mg/L) and taurocholate (0.1%) as previously described
[11]. After 48 hours of incubation, to select for spores, 1 mL of
each enrichment broth was added to equal volumes of 96%
alcohol, left at room temperature for at least 60 minutes and
then plated onto C. difﬁcile ChromID agar. All plates were
incubated in an anaerobic chamber (Don Whitley Scientiﬁc,
Shipley, West Yorkshire, UK) at 37°C in an atmosphere con-
taining 80% N2, 10% CO2, and 10% H2. Putative C. difﬁcile
colonies were identiﬁed as described previously [11].
Molecular characterization of C. difﬁcile isolates
All isolates were screened by in-house PCRs for the presence
of tcdA and tcdB, and binary toxin genes (cdtA and cdtB) [11], and
PCR ribotyping was performed as previously described [12].
Isolates that could not be identiﬁed with the reference library
were designated with an internal nomenclature, preﬁxed with
QX.ResultsIsolation of C. difﬁcile from patients stool specimens
In total, 23.7% (100/422) of the specimens were positive via
direct culture, yielding 105 isolates (four specimens contained
more than one strain). The rest of the specimens (76.3%; 322/
422) were negative by both direct and enrichment culture
techniques (Table 1). The isolation rates for C. difﬁcile from
specimens routinely tested with the BD MAX Cdiff assay and
those not tested were 24.1% (89/370) and 21.2% (11/52),
respectively.
Toxin gene proﬁling and PCR ribotyping of C. difﬁcile
isolates
As shown in Table 1, the overall prevalence of toxigenic
C. difﬁcile was 9.2% (39/422). Of the toxigenic isolatesiology and Infectious Diseases, NMNI, 15, 27–32
nses/by-nc-nd/4.0/).
TABLE 1. Summary of the BD MAX Cdiff assay and toxigenic
culture results
BD MAX Culture Toxin proﬁle Specimens, n (%) Isolates, n (%)
Positive Positive A+B+CDT− 16 (3.8) 16 (15.2)a
A−B+CDT− 8 (1.9) 8 (7.6)
A−B−CDT− 2 (0.5) 5 (4.8)a
Positive Negative — 12 (2.8) —
Negative Positive A+B+CDT− 7 (1.7) 7 (6.7)
A−B+CDT− 4 (0.9) 4 (3.8)
A−B−CDT− 52 (12.3) 54 (51.4)b
Negative Negative — 269 (63.7) —
Untested Positive A+B+CDT− 4 (0.9) 4 (3.8)
A−B−CDT− 7 (1.7) 7 (6.7)
Untested Negative — 41 (9.7) —
Total 422 105
aOne specimen contained two strains, one toxigenic and one nontoxigenic. Only
the toxigenic isolate was included in the ﬁnal calculation to evaluation of the BD
MAX Cdiff assay performance. Additionally, another BD MAX–positive specimen
contained three strains, all of which were nontoxigenic. Only one of the three was
included in the ﬁnal calculation.
bTwo specimens contained two strains each.
TABLE 2. Summary of Clostridium difﬁcile PCR ribotypes and
toxin proﬁles
PCR ribotype
Toxin proﬁle
n (%)tcdA tcdB cdtA/B
014/020 groupa +/− +/− − 17 (16.2)
010 − − − 12 (11.4)
017 − + − 12 (11.4)
039 − − − 9 (8.6)
009 − − − 6 (5.7)
QX 002 − − − 5 (4.8)
QX 178 − − − 4 (3.8)
QX 514 − − − 3 (2.9)
QX 001 + + − 2 (1.9)
QX 083, QX 107, QX 190, QX 506,
QX 511 and QX 524 (2 each)
− − − 12 (11.4)
005, 103, QX 026, QX 032, QX 102,
QX 161, QX 176, QX 455 and
QX 517 (1 each)
+ + − 9 (8.6)
QX 011, QX 077, QX 078, QX 117,
QX 138, QX 507, QX 508, QX
509, QX 510, QX 513, QX 515,
QX 516, QX 522 and QX 523
(1 each)
− − − 14 (13.3)
Total 105
aRT 014/020 group contains 16 A+B+CDT− isolates and one nontoxigenic isolate.
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were A−B+. None of the isolate was positive for the binary
toxin genes cdtA or cdtB. Thus, the majority of isolates recov-
ered did not carry any toxin genes and were therefore
considered nontoxigenic (62.9%; 66/105).
The 38 RTs identiﬁed are shown in Table 2 along with their
respective toxin proﬁle. Of the 105 isolates, 55.2% (58/105)
were assigned to internationally recognized RTs 005 (n = 1),
009 (n = 6), 010 (n = 12), 014/020 group (n = 17), 017 (n = 12),
039 (n = 9) and 103 (n = 1). The remaining 44.8% (47/105) of
the isolates did not match any reference strains and were
designated with an internal nomenclature (Table 2).
Assessment of BD MAX Cdiff assay performance
Of the 370 specimens tested with the BD MAX Cdiff assay, 38
(10.3%) and 332 (89.7%) were BD MAX positive and negative,
respectively (Table 1). When compared against the toxigenic
culture results, 79.2% (293/370) of the specimens were
concordant.
The performance of BD MAX Cdiff assay was calculated after
excluding the BD MAX negative specimens that yielded non-
toxigenic isolates (n = 52). With toxigenic culture as a reference
standard, the sensitivity, speciﬁcity, positive predictive value
(PPV) and negative predictive value (NPV) of the BD MAX Cdiff
assay, and their corresponding 95% conﬁdence intervals (in pa-
rentheses) were 68.6% (50.7–83.1), 95.1% (91.9–97.3), 63.2%
(46.0–78.2) and 96.1% (93.1–98.0), respectively.DiscussionA major risk factor associated with CDI is prior exposure to
antibiotics [13]. Given the healthcare system in Thailand, which
allows drugstores to freely distribute oral antibiotics and© 2016 The Authors. Published by Elsevier Ltd on behal
This is an open access articpatients to self-medicate, antibiotic misuse is prevalent [14].
Apart from encouraging the development of antibiotic resis-
tance, such practices also increase the risk of CDI [13]. To
assess the prevalence and molecular epidemiology of circulating
C. difﬁcile in Thailand, toxigenic culture was performed on 422
diarrhoeal stool specimens obtained from adult patients
admitted at Siriraj Hospital in Bangkok.
By toxigenic culture, the prevalence of toxigenic C. difﬁcile
was 9.2%. Previous studies have reported the prevalence of
CDI in Thailand to range between 4.8 and 52.2%, depending on
the study protocol and population investigated [7]. Since 2000,
two studies have investigated the prevalence of CDI among
patients at Siriraj Hospital using a culture-based technique to
isolate C. difﬁcile and an in-house PCR to investigate the pres-
ence of toxin genes. In 2001, Wongwanich et al. [15] reported
the prevalence of C. difﬁcile among adult patients to be 25.0%
(33/132) and that of toxigenic strains to be 13.6% (18/132).
Although the prevalence of toxigenic C. difﬁcile was slightly
higher than that observed in the current study, it is still likely to
be an underestimation at the time, as the authors only inves-
tigated the presence of tcdA. In 2003, a lower overall prevalence
of C. difﬁcile was reported among patients admitted at Siriraj
Hospital (18.6%; 107/574). The prevalence of toxigenic
C. difﬁcile was 9.1% (52/574), all of which were positive for tcdA
and tcdB [16]. The prevalence in the latter publication more
closely resembled that seen in the current study and could
suggest that the prevalence of CDI in Thailand has remained
constant during the past decade.
As mentioned, the laboratory detection method used and
the characteristics of the cohort under investigation affect the
outcomes of any prevalence study. Compared to otherf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 15, 27–32
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ture and toxin gene detection by a PCR-based technique, the
prevalence of toxigenic C. difﬁcile in Thailand (9.2%) appeared to
be lower than that reported in 2015 for China (19.2%, 80/416)
[17] and similar to that reported in 2015 for India (10.9%, 121/
1110) [18]. These ﬁgures are all higher than those reported in
2015 for Spain (6.0%, 108/1800) [19] and Australia (6.4% to
7.2%) [11,20]. Many studies conducted in Asia have investigated
the prevalence of toxigenic C. difﬁcile using direct detection of
preformed toxins in stool. In 2014, a prevalence of toxigenic
C. difﬁcile similar to that of the current study was reported in
Singapore (9.6%; 158/1642). That study used membrane-type
EIA (C.DIFF Quik Chek Complete; TechLab, Blacksburg, VA,
USA) to detect the presence of glutamate dehydrogenase and
preformed toxins A and B, and the PCR-based Xpert C. difﬁcile
test (Cepheid, Sunnyvale, CA, USA) to detect the presence of
tcdB [21]. On the basis of the existing data, the prevalence of
CDI in Asia ranges between approximately 9.0 and 20.0%. The
prevalence appeared to be lower among developed countries.
A high prevalence of A−B+ (RT 017) strains was noted in the
current study (11.4%), in contrast to the report by Wongwa-
nich et al. [16] for the same hospital in 2003. To detect the
presence of tcdA, the authors used only the primer sequences
which targets the nonrepeating region of tcdA (NK2 and NK3)
described by Kato et al. [22]. Some strains of C. difﬁcile,
including RT 017, possess a deletion in the repeating region of
tcdA, rendering the toxin nonfunctional. To detect the deletion,
an additional primer pair (NK9 and NK11) is required, and
failure to use these could explain the absence of A−B+ strains in
their report [22].
Interestingly, a high prevalence of nontoxigenic C. difﬁcile was
observed in this study (15.6%). Previous studies from Thailand
have reported the prevalence of nontoxigenic strains to be
9.6% (55/574) [16]. Studies conducted in China and India re-
ported the prevalence of nontoxigenic isolates to be 7.7% (32/
416) and 4.8% (53/1110), respectively [17,18]. There is some
evidence suggesting an association between asymptomatic car-
riage of either toxigenic or nontoxigenic C. difﬁcile, and a sub-
sequent systemic anamnestic response of serum IgG antibody
against toxin A leading to a reduced risk of developing CDI [23].
Given the high prevalence of nontoxigenic C. difﬁcile, it is
possible that such a mechanism plays a protective role against
CDI in Asia.
Among the specimens investigated, 12.3% were stools sub-
mitted for non–C. difﬁcile–related tests. The prevalence of
toxigenic C. difﬁcile among this population was 7.7%. Although
these may represent missed cases of CDI, it is possible that
C. difﬁcile testing was not requested because of a lack of clinical
suspicion. This could not be conﬁrmed, as no clinical data were
collected. Furthermore, some recent studies suggest that© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
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commonly than previously thought, in 7 to 15% of healthy
adults [24]. Further investigation is required to better interpret
the signiﬁcance of such missed cases.
Using toxigenic culture as the reference standard, the sensi-
tivity, speciﬁcity, PPV and NPV of the BD MAX Cdiff assay were
68.6, 95.1, 63.2 and 96.1%, respectively. The values appeared
inferior to the previously reported sensitivity, speciﬁcity, PPV
and NPV ﬁgures for BD MAX (94.0–97.7, 97.9–99.7, 87.5–97.7
and 98.9–99.7%, respectively) [11]. It is possible that patients
may have been exposed to antibiotics before the stool collec-
tion. In such scenarios, BD MAX may have detected the pres-
ence of tcdB released by the dead C. difﬁcile, leading to a relatively
higher number of false-positive results. One possible explanation
of false-negative ﬁndings might be an alteration in the tcdB
sequence, rendering it unrecognizable by the BD MAX Cdiff
assay. However, this was not the case, as isolates from all false-
negative samples signalled positive upon retesting on the BD
MAX assay. False-negative results may occur as a result of the
low bacterial load in the stool specimens.
The ﬁve most prevalent RTs were 014/020 group (16.2%),
010 (11.4%), 017 (11.4%), 039 (8.6%) and 009 (5.7%). An earlier
study investigating the molecular epidemiology of C. difﬁcile
collected between 2006 and 2008 from inpatients at Siriraj
Hospital also reported RTs 017 (41.5%) and 014/020 group
(20.7%) among the top RTs [9]. Additionally, RT 014/020 group
was reported to be highly prevalent among humans in Australia
[20], Korea [25], Europe [19,26] and North America [27]. In
contrast, RT 046, which was previously reported as the third
most common RT at Siriraj Hospital (6/53), was not found [9].
The second most common RT, 017, is highly prevalent in Asian
countries, including China, Japan, Korea and Taiwan [28]. RT
017 has also caused signiﬁcant epidemics in the Netherlands
and Ireland [29].
Reports on nontoxigenic C. difﬁcile in Asia are scarce.
Hawkey et al. [30] identiﬁed two isolates of RT 009 from 21
culture-positive specimens collected from patients in China.
The lack of reporting has likely stemmed from the fact that
most molecular studies conducted in Asia focussed on the
characterization of the toxigenic strains [28]. As such, the
prevalence and molecular characteristics of nontoxigenic
strains such as RTs 009, 010 and 039 observed in this study may
have largely gone undocumented.
In addition to the top ﬁve RTs, 33 other RTs were observed,
the majority of which were novel and did not match the PCR
ribotyping patterns available in the reference library. Such a
great heterogeneity could suggest a previously undeﬁned and
widely distributed reservoir of infection in Thailand. Further-
more, the absence of binary toxin producers, the lack of
hypervirulent RTs 027 and 078 and the high prevalence ofiology and Infectious Diseases, NMNI, 15, 27–32
nses/by-nc-nd/4.0/).
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circulating in Thailand may be different from that in other parts
of the world. Epidemiologic studies involving humans, com-
panion and production animals, and the environment would
shed light in possible sources of infection in both Thai health-
care facilities and communities.
CDI is common in Thailand, and continuing surveillance and
research are required to monitor its changing epidemiology.
Misuse of antibiotics remains a major driver of CDI in Asia, and
greater efforts must be made to encourage antibiotic stew-
ardship by healthcare practitioners and the public.AcknowledgementsWe thank staff in the Microbiology Department at Siriraj
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